Torax Medical, based in Shoreview, Minnesota, has raised $4 million by issuing debt and is seeking another $4 million in funding, according to a recent regulatory filing.
It appears that the company, which is focused on the minimally invasive treatment of gastroesophageal reflux disease, raised $18 million in 2009, $10 million in 2005 and another $3.5 million in 2004. All three previous financing rounds were in exchange for equity.
Previous investors in the company include Thomas McNerney & Partners, Sanderling Ventures, Mayo Medical Ventures and Accuitive Medical Ventures. Torax Medical has applied for a premarket approval for its Linx Anti-Reflux Treatment, which is approved in Europe and has been available there since April 2010. The Linx device is designed to strengthen an abnormal sphincter — the muscle that is supposed to bar stomach acids from escaping into the esophagus — and restore it to its proper function.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s vice president of finance was traveling and Todd Berg, Torax’s co-founder, president and CEO, did not respond to an email request for an interview.